I-Mab (IMAB) News Today $4.89 -0.18 (-3.45%) As of 03:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMAB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period I-Mab's (IMAB) Sell (D+) Rating Reiterated at Weiss RatingsOctober 9 at 4:26 AM | marketbeat.comI-Mab (NASDAQ:IMAB) Upgraded to "Buy" at Wall Street ZenOctober 6 at 2:43 AM | americanbankingnews.comI-Mab (NASDAQ:IMAB) Upgraded at Leerink PartnrsOctober 6 at 2:07 AM | americanbankingnews.comLeerink Partners Initiates Coverage of I-Mab - Depositary Receipt (IMAB) with Outperform RecommendationOctober 4, 2025 | msn.comI-Mab (NASDAQ:IMAB) Upgraded to Strong-Buy at Leerink PartnrsOctober 4, 2025 | marketbeat.comI-Mab (NASDAQ:IMAB) Upgraded to Buy at Wall Street ZenOctober 3, 2025 | marketbeat.comI-Mab initiated with an Outperform at LeerinkOctober 3, 2025 | msn.comI-Mab Sponsored ADR (NASDAQ:IMAB) Given Average Rating of "Buy" by AnalystsOctober 3, 2025 | marketbeat.comI-Mab to Vote on Name Change to NovaBridge BiosciencesSeptember 25, 2025 | msn.comI-Mab (IMAB) Shows 83% Response Rate for Givastomig in Metastatic Gastric CancerSeptember 23, 2025 | msn.comI-Mab (NASDAQ:IMAB) Rating Lowered to "Hold" at Wall Street ZenSeptember 20, 2025 | marketbeat.comI-Mab (NASDAQ:IMAB) Earns Buy Rating from Analysts at BTIG ResearchSeptember 11, 2025 | marketbeat.comI-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By MarketSeptember 10, 2025 | seekingalpha.comNeedham & Company LLC Reaffirms Buy Rating for I-Mab (NASDAQ:IMAB)September 10, 2025 | marketbeat.comBTIG Initiates Coverage of I-Mab - Depositary Receipt () (IMAB) with Buy RecommendationSeptember 9, 2025 | msn.comI-Mab initiated with a Buy at BTIGSeptember 9, 2025 | msn.comI-Mab Announces Leadership Changes and Accelerated Investment in GivastomigSeptember 9, 2025 | msn.comI-Mab announces accelerated investment in givastomig programSeptember 9, 2025 | msn.comI-Mab Announces Acceleration of Givastomig Investment and Leadership AppointmentsSeptember 9, 2025 | markets.businessinsider.comI-Mab to accelerate investment in givastomigSeptember 9, 2025 | msn.comI-Mab Sponsored ADR (NASDAQ:IMAB) Sees Large Increase in Short InterestSeptember 5, 2025 | marketbeat.comI-Mab Insiders Land Bargain With Gains Of US$5.0mAugust 31, 2025 | finance.yahoo.comStonepine Capital Management LLC Makes New $398,000 Investment in I-Mab Sponsored ADR $IMABAugust 26, 2025 | marketbeat.comHC Wainwright Comments on I-Mab's Q3 Earnings (NASDAQ:IMAB)August 26, 2025 | marketbeat.comI-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development CommitteeAugust 25, 2025 | globenewswire.comI-Mab (NASDAQ:IMAB) Upgraded by Wall Street Zen to "Buy" RatingAugust 25, 2025 | marketbeat.comNeedham & Company LLC Forecasts Strong Price Appreciation for I-Mab (NASDAQ:IMAB) StockAugust 23, 2025 | marketbeat.comI-Mab's (IMAB) Buy Rating Reiterated at HC WainwrightAugust 23, 2025 | marketbeat.comI-Mab (NASDAQ:IMAB) Announces Earnings Results, Beats Estimates By $0.03 EPSAugust 22, 2025 | marketbeat.comI-Mab Biopharma: I-Mab Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 21, 2025 | finanznachrichten.deI-Mab to Participate in September Investor ConferencesAugust 21, 2025 | globenewswire.comI-Mab (IMAB) Expected to Announce Earnings on WednesdayAugust 21, 2025 | marketbeat.comI-Mab Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 20, 2025 | tmcnet.comI-Mab price target raised to $6 from $5 at NeedhamAugust 20, 2025 | msn.comI-Mab Reports Strong Financials and Clinical Progress in August 2025August 20, 2025 | msn.comI MAB (ADS) options imply 11.8% move in share price post-earningsAugust 19, 2025 | msn.comGround Swell Capital LLC Takes Position in I-Mab Sponsored ADR (NASDAQ:IMAB)August 17, 2025 | marketbeat.comI-Mab (NASDAQ:IMAB) Trading 14.1% Higher - Here's WhyAugust 12, 2025 | marketbeat.comEverest Medicines announces strategic equity investment in I-MabAugust 1, 2025 | msn.comEverest Medicines Expands Strategic Investment in I-MABAugust 1, 2025 | prnewswire.comI-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary SharesAugust 1, 2025 | globenewswire.comI-Mab (NASDAQ:IMAB) Lowered to "Hold" Rating by Wall Street ZenJuly 20, 2025 | marketbeat.comI-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge HealthJuly 17, 2025 | globenewswire.comI-Mab to Present at the BTIG Virtual Biotechnology ConferenceJuly 14, 2025 | finance.yahoo.comI-Mab (NASDAQ:IMAB) Raised to Buy at Wall Street ZenJuly 12, 2025 | marketbeat.comI-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025July 9, 2025 | msn.comI-Mab (NASDAQ:IMAB) Given Buy Rating at HC WainwrightJuly 9, 2025 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for I-Mab (NASDAQ:IMAB)July 9, 2025 | marketbeat.comI-Mab Reports Encouraging Phase 1b Data for Givastomig in Combination with Nivolumab and mFOLFOX6 at ESMO GI 2025, Confirming 83% Objective Response Rate in Gastric ... - NasdaqJuly 4, 2025 | nasdaq.comI-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025July 2, 2025 | globenewswire.com Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMAB Media Mentions By Week IMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMAB News Sentiment▼0.550.63▲Average Medical News Sentiment IMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMAB Articles This Week▼102▲IMAB Articles Average Week Get the Latest News and Ratings for IMAB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for I-Mab and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Stoke Therapeutics News LENZ Therapeutics News Syndax Pharmaceuticals News Sionna Therapeutics News Xeris Biopharma News Taysha Gene Therapies News Zymeworks News Nuvation Bio News Ardelyx News Amphastar Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMAB) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
